Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone858-366-6900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$183.87 million
Profitability
Miscellaneous
Employees653
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions
What is Tandem Diabetes Care's stock symbol?
Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."
When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?
Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.
How were Tandem Diabetes Care's earnings last quarter?
Tandem Diabetes Care Inc (NASDAQ:TNDM) announced its quarterly earnings data on Thursday, August, 1st. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.20. The medical device company had revenue of $93.26 million for the quarter, compared to the consensus estimate of $69.95 million. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The company's quarterly revenue was up 173.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.33) earnings per share. View Tandem Diabetes Care's Earnings History.
When is Tandem Diabetes Care's next earnings date?
What guidance has Tandem Diabetes Care issued on next quarter's earnings?
Tandem Diabetes Care updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $350-365 million, compared to the consensus revenue estimate of $312.78 million.
What price target have analysts set for TNDM?
14 analysts have issued 12 month target prices for Tandem Diabetes Care's stock. Their forecasts range from $50.00 to $100.00. On average, they anticipate Tandem Diabetes Care's share price to reach $71.4286 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price. View Analyst Price Targets for Tandem Diabetes Care.
What is the consensus analysts' recommendation for Tandem Diabetes Care?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.
Has Tandem Diabetes Care been receiving favorable news coverage?
Media headlines about TNDM stock have trended positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tandem Diabetes Care earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Tandem Diabetes Care.
Who are some of Tandem Diabetes Care's key competitors?
Some companies that are related to Tandem Diabetes Care include Novocure (NVCR), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), ICU Medical (ICUI), NuVasive (NUVA), Nevro (NVRO), Glaukos (GKOS), Merit Medical Systems (MMSI) and Irhythm Technologies (IRTC).
What other stocks do shareholders of Tandem Diabetes Care own?
Who are Tandem Diabetes Care's key executives?
Tandem Diabetes Care's management team includes the folowing people:
- Mr. Kim D. Blickenstaff, Exec. Chairman (Age 67)
- Mr. John F. Sheridan, Pres & CEO (Age 64)
- Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)
- Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)
- Mr. Manuel Jaime, Sr. VP of Technology & Digital Health
Who are Tandem Diabetes Care's major shareholders?
Tandem Diabetes Care's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.62%), BlackRock Inc. (6.91%), BlackRock Inc. (6.91%), TimesSquare Capital Management LLC (1.96%), Eagle Asset Management Inc. (1.73%) and Renaissance Technologies LLC (1.53%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.
Which institutional investors are selling Tandem Diabetes Care stock?
TNDM stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., First Light Asset Management LLC, TimesSquare Capital Management LLC, Ardevora Asset Management LLP, Orbimed Advisors LLC, AQR Capital Management LLC and JPMorgan Chase & Co.. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.
Which institutional investors are buying Tandem Diabetes Care stock?
TNDM stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Balyasny Asset Management LLC, Chicago Capital LLC, Allianz Asset Management GmbH, Calamos Advisors LLC, Wells Fargo & Company MN and Stephens Investment Management Group LLC. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.
How do I buy shares of Tandem Diabetes Care?
Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tandem Diabetes Care's stock price today?
One share of TNDM stock can currently be purchased for approximately $66.81.
How big of a company is Tandem Diabetes Care?
Tandem Diabetes Care has a market capitalization of $3.92 billion and generates $183.87 million in revenue each year. The medical device company earns $-122,610,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Tandem Diabetes Care employs 653 workers across the globe.View Additional Information About Tandem Diabetes Care.
What is Tandem Diabetes Care's official website?
How can I contact Tandem Diabetes Care?
Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]
MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
